---
title: "PRF Technologies readies Phase 2 trial of LayerBio’s OcuRing-K cataract surgery implant"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293935329.md"
description: "PRF Technologies is preparing to initiate a Phase 2 clinical trial for LayerBio’s OcuRing-K, an implant designed for use during cataract surgery. The update highlights readiness work rather than presenting clinical results. The device aims to serve as an alternative to post-surgical eye drops, potentially simplifying patient care and improving comfort."
datetime: "2026-07-27T12:48:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293935329.md)
  - [en](https://longbridge.com/en/news/293935329.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293935329.md)
---

# PRF Technologies readies Phase 2 trial of LayerBio’s OcuRing-K cataract surgery implant

-   PRF Technologies flagged preparations to start a planned Phase 2 trial of LayerBio’s OcuRing-K for use during cataract surgery. \* No clinical results were presented; the update focused on readiness work ahead of trial initiation. \* The program is positioned as a potential alternative to eye drops, aiming to simplify post-surgery care and improve patient comfort. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PRF Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003581), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PRFX.US](https://longbridge.com/en/quote/PRFX.US.md)

## Related News & Research

- [EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain](https://longbridge.com/en/news/284380452.md)
- [Quirónsalud Dexeus study links oral contraceptives to improved ACL graft maturation in women post-surgery](https://longbridge.com/en/news/295370473.md)
- [Beta Technologies CEO Clark Kyle disposes of common shares worth $1.17 million](https://longbridge.com/en/news/295587405.md)
- [L1 Capital reports disposal of Anteris Technologies common shares worth USD 5.76 million](https://longbridge.com/en/news/295648130.md)
- [L1 Capital reports sale of 174,721 Anteris Technologies common shares valued at $1.42 million](https://longbridge.com/en/news/295398611.md)